值得注意的是，预订哈尔滨行程的用户中，超过30% 的用户在行程规划中同时包含了冰雪大世界与哈 尔滨极地公园两大景区，"冰雪+极地"的差异化组合体验正成为游客探索哈尔滨的经典之选。憨态可掬 的"淘学企鹅"、精彩绝伦的白鲸秀"海洋之心"以及丰富的极地动物资源，让哈尔滨极地公园在冰雪旅游 的宏大背景下，提供了独特而温暖的极地魅力体验，有效延长了游客在哈停留时间。 新华社消息，第二十七届哈尔滨冰雪大世界将于2025年12月17日10时开园。作为世界级冰雪旅游目的 地，其开园消息瞬间点燃了全国游客的出游热情。同程旅行平台数据显示，截至12月15日上午9点， 与"哈尔滨冰雪大世界"相关的搜索热度相较前日同期暴涨5倍，而12月以来，哈尔滨冰雪大世界相关搜 索热度持续攀升，带动冬季旅游热潮，哈尔滨荣登平台冬季热门旅游目的地榜首。 冰雪大世界的璀璨冰灯与恢弘雪雕，无疑是今冬哈尔滨吸引游客的"金字招牌"。同程旅行平台上，相关 门票套餐预订热度在预售期就呈现爆发式增长。冰雪大世界开园的火爆，也进一步带动了哈尔滨整体旅 游热度，其中哈尔滨极地公园表现尤为亮眼。同程旅行平台数据显示，自11月冰雪旅游季预热启动以 来，哈尔滨极地公园的搜 ...

Core Insights - The collaboration between Fliggy and the seventh-ranked Korean duty-free store, Hanseong New World, offers exclusive benefits for travelers planning to shop in South Korea [1][3] Group 1: Partnership Benefits - Fliggy members will enjoy comprehensive exclusive rights, including discounts for both online orders and in-store purchases at two airport locations and one city store [3] - Customers can unlock additional rewards upon reaching spending thresholds, effectively reducing expenses [3] - The Fliggy App will provide continuous updates on discount information, ensuring travelers are informed before departure, during their stay, and after returning [3] Group 2: Travel Convenience - South Korea remains a popular outbound travel destination for Chinese tourists, ranking among the top five overseas destinations for Fliggy's Double 11 shopping event [3] - The South Korean government has implemented a visa-free entry policy for group tourists from China, effective from September 29 until June 30 of the following year, allowing groups of three or more to stay for 15 days [3] - Individual and group tourists can continue to enjoy a 30-day visa-free stay in Jeju Island, maintaining previous regulations [3]

Core Viewpoint - The Yunnan Provincial Tourism Homestay Industry Association has initiated collective legal action against online travel agencies (OTAs) like Ctrip for alleged abuse of market dominance, raising concerns about unfair competition practices in the homestay sector [1] Group 1: Allegations Against OTAs - The association has received multiple complaints from its members regarding OTAs using their market power to impose unfair practices, including "choose one from two" clauses, arbitrary commission increases, and unfair trading conditions [1] - These practices are said to severely infringe on the rights of homestay operators and disrupt fair market competition, hindering the healthy development of the industry [1] Group 2: Association's Response and Actions - The association's president, He Shuangquan, emphasized the need for fair competition and criticized the coercive practices of OTAs that force homestays to choose specific platforms [1] - The first step in their action plan involves collecting evidence from affected homestays to support a collective lawsuit to the market supervision authority [1] Group 3: Commission and Fee Concerns - He Shuangquan noted that while commissions typically range from 8% to 15%, some OTAs charge hidden fees that can lead to total commission rates as high as 30% to 40% [1] - This high fee structure raises questions about the actual market and profit space available for homestays, as platforms often earn more than the service providers themselves, leading to concerns about the sustainability of the business model [1]

Core Viewpoint - The Yunnan Provincial Tourism Homestay Industry Association has initiated collective legal action against online travel platforms (OTAs) like Ctrip for alleged abuse of market dominance, raising concerns about unfair competition practices in the homestay industry [1][4]. Group 1: Allegations Against OTAs - The association has received multiple complaints from its members regarding OTAs using their market power to impose unfair practices, including "choose one from two" clauses, arbitrary commission increases, unfair trading conditions, and traffic blocking [1][4]. - These practices are said to severely infringe on the legitimate rights of homestay operators, disrupt fair market competition, and hinder the healthy development of the industry [1][4]. Group 2: Association's Response and Actions - The association's president, He Shuangquan, emphasized the need for fair competition and criticized the notion that platforms should dictate which apps users must use or force homestays to align with specific platforms [1][4]. - The first step in their action plan involves collecting evidence from affected homestays to support a collective lawsuit to be submitted to the market supervision administration [1][4]. Group 3: Commission and Fee Concerns - He Shuangquan noted that while commissions typically range from 8% to 15%, hidden platform fees can lead to total commission rates as high as 30% to 40%, raising questions about the market and profit space for homestays [1][4]. - The president pointed out that the revenue generated by homestays is often viewed as a source of income for the platforms, resulting in platforms earning more than the service providers themselves, which he described as "blood money" [1][4].

Core Insights - The article discusses the evolving trends in the cultural and tourism consumption market, highlighting a shift from "check-in" experiences to "immersive" experiences [1][2] Group 1: Market Trends - The cultural and tourism consumption market is undergoing profound changes across four dimensions: destination, consumption philosophy, customer demographics, and engagement methods [1] - Destinations are being redefined from mere attractions to experiential "fields," integrating cultural tourism with everyday life scenarios, offering richer and more layered choices for tourists [1] - There is a notable trend towards "decentralization" and "de-scenicization," with tourism heat in lower-tier cities increasing by 25% year-on-year during the recent May Day holiday [1] Group 2: Consumer Behavior - Consumers are becoming more "value-sensitive," with a significant increase in rational segmentation of spending [1] - The trend of "slow immersion" is evident, with the proportion of users staying for two days or more rising by 7.2%, and searches for deep immersive activities increasing by 300% year-on-year, indicating a strong willingness to pay for immersive experiences [1] Group 3: Demographic Drivers - The Z generation and the "new silver-haired" demographic are identified as dual engines driving market innovation, with the former favoring social and immersive experiences, while the latter seeks quality deep travel [2] - These two groups contribute to market innovation by leading trends in engagement and defining quality experiences [2]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical sector, highlighting ongoing commercialization and active business development opportunities [16]. Core Insights - The 2025 National Medical Insurance Directory and the first version of the Commercial Health Insurance Innovative Drug Directory were released, adding 114 new drugs, including 111 new drugs approved within the last five years. The success rate for negotiations was 88.19% [6][7]. - Fosun Pharma's subsidiary has licensed an oral GLP-1 drug to Pfizer, with potential milestone payments totaling up to $15.85 billion [3][7]. - The report emphasizes the importance of clinical progress in key pipelines for companies like BeiGene, Innovent Biologics, and others [9]. Summary by Sections Domestic Policy Developments - The 2025 National Medical Insurance Directory includes 114 new drugs, with 112 successfully negotiated from 127 that entered the bidding process. Most renewals were completed at original prices, with an average price reduction of 8.4% for 15 drugs [6][7]. Domestic Pharmaceutical Company Updates - Fosun Pharma's subsidiary has signed a licensing agreement with Pfizer for the oral GLP-1R agonist, with an upfront payment of $150 million and potential milestone payments [3][7]. - The approval of clinical trials for HLX22 (HER2 monoclonal antibody) for breast cancer treatment has been granted [3][7]. - New clinical data for a BCL2 inhibitor from Innovent Biologics showed promising results in treating various blood cancers [3][7]. International Pharmaceutical Company Updates - Wave Life Sciences reported positive Phase I data for WVE-007, showing significant reductions in visceral fat and overall body fat after treatment [8]. - Structure Therapeutics announced positive results for its oral GLP-1R agonist, achieving notable weight loss in clinical trials [8]. - Roche received EU approval for Gazyva/Gazyvaro for treating lupus nephritis, marking a significant advancement in autoimmune disease treatment [8]. Investment Recommendations - The report suggests focusing on innovative drugs and companies with active business development opportunities, particularly in the context of ongoing clinical advancements [9].

2025年12月12日，在中国旅游研究院、中国旅游协会共同主办的"2025中国旅游集团化发展论坛"上，飞 猪入选"2025中国旅游集团20强"。一同入选的还有中国旅游集团、华侨城集团、首旅集团、中青旅控 股、锦江国际集团、携程集团、春秋集团等。 从2009年开始，中国旅游研究院发起中国旅游集团专题调查，迄今已连续开展17年。本年度中国旅游集 团20强，继续根据企业申报、诚信背书的原则，按照营业收入决定入围名单。 今年以来，飞猪增长曲线持续上扬，并多次刷新纪录。在刚刚过去的双11，飞猪平台大促、日销双双强 劲增长，整体履约GMV较去年增长30%。在出游高峰的"十一"假期，飞猪旅游服务履约GMV较去年增 长48%，服务人次较去年增长30%，倍数级领涨旅游市场。 旅游商家也在飞猪收获了高增长。今年双11，飞猪平台GMV破亿品牌，最高接近10亿元。GMV超过 1000万元的活动商家数量同比增长约30%，其中旅行社商家数量同比增长160%。不少首次参加双11的 中小商家也收获了100万元以上的好业绩。 专家认为，基于飞猪开放平台模式，商家可在平台上自主经营，发展品牌、沉淀会员资产，进而提升用 户黏性和复购。这种模式更侧 ...

Investment Rating - The report maintains a positive outlook on the overseas pharmaceutical sector, particularly highlighting the recent developments in drug approvals and partnerships [1][5]. Core Insights - The 2025 National Medical Insurance Directory and the first version of the commercial health insurance innovative drug directory were released, adding 114 new drugs, including 111 new drugs approved within the last five years. The success rate for negotiations was 88.19% [1][6]. - Fosun Pharma's subsidiary has licensed an oral GLP-1 drug to Pfizer, with potential milestone payments totaling up to $15.85 billion [2][7]. - The report emphasizes the importance of ongoing clinical trials and the introduction of innovative drugs in the market, which are expected to drive growth in the pharmaceutical sector [10]. Summary by Sections Domestic Policy Developments - The 2025 National Medical Insurance Directory includes 114 new drugs, with 112 successfully negotiated from 127 that entered the bidding process. Most renewal drugs were renewed at original prices, with an average price reduction of 8.4% for 15 drugs [6][7]. Domestic Pharmaceutical Company Updates - Fosun Pharma's subsidiary has signed a licensing agreement with Pfizer for the global development and commercialization of an oral GLP-1R agonist, with an upfront payment of $150 million and potential milestone payments [2][7]. - The approval of clinical trials for HER2 monoclonal antibodies for breast cancer treatment has been granted, indicating progress in innovative cancer therapies [2][7]. - New clinical data for a BCL2 inhibitor was presented, showing promising efficacy and safety in treating various blood cancers [2][7]. Overseas Pharmaceutical Company Updates - Wave Life Sciences reported positive Phase I data for an siRNA drug targeting obesity, showing significant reductions in visceral fat and overall body fat [3][9]. - Structure Therapeutics announced positive results for its oral GLP-1 small molecule, demonstrating substantial weight loss in clinical trials [3][9]. - Roche received EU approval for a CD20 monoclonal antibody for treating lupus nephritis, marking a significant advancement in autoimmune disease therapies [3][9]. Investment Recommendations - The report suggests focusing on innovative drugs and companies with active business development opportunities, particularly those with promising clinical pipelines [10].

Core Insights - The snowfall in Beijing has led to a significant increase in search interest for major tourist attractions, particularly the Palace Museum and Universal Beijing Resort [1][2] - Ticket sales for the Palace Museum are sold out for the weekend of December 13-14, with a notable increase in booking interest for deep-dive tours and day trips [1][2] - Universal Beijing Resort has also seen a surge in ticket bookings, with an increase of over 80% compared to the previous week [1][2] Summary by Category - **Weather Impact**: Snowfall has affected various districts in Beijing, resulting in medium to heavy snow in most areas and localized blizzards [1][2] - **Tourism Trends**: The search volume for "Palace Museum" surged by 90% and for "Universal Beijing Resort" by over 40% compared to the previous two days [1][2] - **Booking Data**: The booking interest for the Palace Museum's weekend tours has more than doubled compared to the previous week, while Universal Beijing Resort's ticket bookings have increased significantly [1][2]

Group 1 - The first snowfall of 2025 in Beijing has led to a surge in interest for winter tourism, particularly in popular attractions like the Forbidden City and Universal Beijing Resort [1] - Search volume for the Forbidden City increased by 90% and for Universal Beijing Resort by over 40% compared to the previous two days [1] - Tickets for the Forbidden City on December 13 and 14 have sold out, with deep-dive tour packages and day trip products seeing over a 100% increase in bookings compared to the previous week [1] Group 2 - Due to the high demand for tickets to the Forbidden City and Universal Beijing Resort, visitors are turning to other scenic spots suitable for snow viewing, resulting in increased popularity for historical buildings and parks [2] - Attractions such as Summer Palace, Yuanmingyuan, Temple of Heaven, Yonghe Temple, Jingshan Park, Beihai Park, and Badaling Great Wall have entered the top 10 popular scenic spots [2]